News & Updates

Low-dose drug combinations that incorporate between three and four blood pressure (BP)-lowering medications appear to be well tolerated and effective for the initial or early management of hypertension, according to the results of a systematic review and meta-analysis.

The use of rivaroxaban in nonhospitalized patients with symptomatic COVID-19 falls short of reducing the composite endpoint of venous and arterial thrombotic events, hospitalization, and death, according to data from PREVENT-HD*.

P2B001, an investigational drug formulation that combines extended release (ER) doses of pramipexole and rasagiline, shows promise in managing Parkinson’s Disease (PD), conferring symptom control similar to that achieved with the marketed ER pramipexole while reducing the troublesome side effect of excessive daytime sleepiness.

Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.

Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.

Use of vitamin D but not calcium supplementation appears effective at preventing multiple sclerosis (MS) in individuals of European descent, suggests a recent study.